Differences in response to treatment in children with severe IgA nephropathy according to patient age

Yukihiko Kawasaki, Yohei Kume, Atsushi Ono, Ryo Maeda, Hayato Go

Author information
  • Yukihiko Kawasaki

    Fukushima Medical University, Regional Medical Support Center
    Department of Pediatrics, Fukushima Medical University School of Medicine

  • Yohei Kume

    Department of Pediatrics, Fukushima Medical University School of Medicine

  • Atsushi Ono

    Department of Pediatrics, Fukushima Medical University School of Medicine

  • Ryo Maeda

    Department of Pediatrics, Fukushima Medical University School of Medicine

  • Hayato Go

    Department of Pediatrics, Fukushima Medical University School of Medicine


Aim: To clarify whether the response to treatment of IgA nephropathy (IgAN) differs depending on patient age, we examined the response to treatment according to age of onset in children with IgAN. Methods: We collected data for 44 children with severe IgAN. The children were retrospectively divided into three groups based on their age at disease onset. Group 1 consisted of 24 children under 11 years old, group 2 consisted of 9 children aged 12 to 13 years, and group 3 consisted of 11 children aged over 14 years old. The clinical features and prognosis were analyzed for each group. Results: The urinary protein excretion and serum IgA values in group 3 were higher than those in groups 1 and 2 at the most recent follow up, and histological findings showed that the MESTCG scores in group 3 were higher than those in group 1. Furthermore, the incidence of patients with persistent nephropathy or renal insufficiency in group 3 was higher than those in groups 1 and 2. Conclusions: Patients aged 14 years and older with IgAN may respond poorly to treatment compared with those younger than 14 years old. Therefore, care must be taken regarding response to treatment and relapse when treating older children.

The cintent of reseach paper


1. Berger J, Hinglais N. Les depots intercapillaireis d’IgA-IgG. J Urol Nephrol, 74:694-695, 1968.

2. Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med, 368:2402-2414, 2013.

3. Andreoli SP, Bergstein JM:Treatment of severe IgA nephropathy in children. Pediatr Nephrol, 3:248-253, 1989.

4. Suzuki H, Kiryluk K, Novak J, et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol, 22:1795-1803, 2011.

5. Kusumoto Y, Takebayashi S, Taguchi T, Harada T, Naito S:Long-term prognosis and prognostic indices of IgA nephropathy in juvenile and in adult Japanese. Clin Nephrol, 28:118-124,1987.

6. Nozawa R, Suzuki J, Isome M, Kawasaki Y, Suzuki S, Suzuki H. Clinicopathological features and the prognosis of IgA nephropathy in Japanese children on long-term observation. Clin Nephrol, 64:171-179, 2005.

7. Yoshikawa N, Ito H, Sakai T, et al. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. J Am Soc Nephrol, 10:101-109, 1999.

8. Kawasaki Y, Suzuki J, Sakai N, et al. Efficacy of prednisolone and mizoribine therapy for disuse IgA nephropathy. Am J Nephrol, 24:147-153, 2004.

9. Kamei K, Nakanishi K, Ito S, et al. Long-term results of a randomized controlled trial in childhood IgA nephropathy. Clin J Am Soc Nephrol, 6:1301-1307, 2011.

10. Kawasaki Y, Suyama K, Miyazaki K, et al. Resistance factors for the treatment of immunoglobulin A nephropathy with diffuse mesangial proliferation. Nephrology (Carlton), 19:384-391, 2014.

11. Ikezumi Y, Suzuki T, Karasawa T, et al. Identification of alternatively activated macrophages in new-onset paediatric and adult immunoglobulin A nephropathy:potential role in mesangial matrix expansion. Histopathology, 58:198-210, 2011.

12. Uemura O, Honda M, Matsuyama T, et al. Is the new Schwartz equation derived from serum creatinine and body length suitable for evaluation of renal function in Japanese children? Eur J Pediatr, 171:1401-1404, 2012.

13. Working Group of the International IgA Nephropathy Network, the Renal Pathology Society, Coppo R, Troyanov S, et al. The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int, 77:921-927, 2010.

14. Nakanishi K, Yoshikawa N. Immunoglobulin A Nephropathy. Section5. Glomerular Disease. In:Avner ED, Harmon WE, Niaudet P, Yoshikawa N (d) Pediatric Nephrology Vol 2 6thEd. Springer 757-782, 2009.

15. Clinical Practice Guidelines for Pediatric IgA Nephropathy 2020 Japan Society for Pediatric Nephropathy / Editing Diagnosis and Treatment https://minds.jcqhc.or.jp/docs/gl_pdf/G0001187/4/iga_nephropathy_in_children.pdf Shindantotiryosya in Japanese

16. Suzuki H, Kikuchi M, Koike K, et al. A digest from evidence-based clinical practice guideline for IgA nephropathy 2020. Clin Exp Nephrol, 25:1269-1276, 2021.

17. Selewski DT, Ambruzs JM, Appel GB, et al. Clinical Characteristics and Treatment Patterns of Children and Adults with IgA Nephropathy or IgA Vasculitis:Findings From the CureGN Study. Kidney Int Rep, 3:1373-1384, 2018.

18. Haas M, Rahman MH, Cohn RA, Fathallah-Shaykh S, Ansari A, Bartosh SM. IgA nephropathy in children and adults:comparison of histologic features and clinical outcomes. Nephrol Dial Transplant, 23:2537-2545, 2008.

19. Cambier A, Rabant M, El Karoui K, et al. Clinical and histological differences between adults and children in new onset IgA nephropathy. Pediatr Nephrol, 35:1897-1905, 2020.

20. Ronkainen J, Ala-Houhala M, Autio-Harmainen H, et al. Long-term outcome 19 years after childhood IgA nephritis:a retrospective cohort study. Pediatr Nephrol, 21:1266-1273, 2006.